CM Life Sciences, Inc. Unit
CMLFU
CMLFU was delisted on the 22nd of July, 2021.
0 hedge funds and large institutions have $0 invested in CM Life Sciences, Inc. Unit in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 17 closing their positions.
100% less funds holding
Funds holding: 17 → 0 (-17)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $80.6M → $0 (-$80.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 17
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.2M |
| 2 |
BCP
Berylson Capital Partners
Boston,
Massachusetts
|
-$15.8M |
| 3 |
GS
Gagnon Securities
New York
|
-$10.3M |
| 4 |
IM
Islet Management
New York
|
-$9.85M |
| 5 |
GA
Gagnon Advisors
New York
|
-$5.84M |
CMLFU Hedge Fund Activity: Q3 2021 in Review
0 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in CM Life Sciences, Inc. Unit (CMLFU) for Q3 2021, worth a combined $0 — down 100% from $80.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CMLFU and 0 opened new positions — a net loss of 17 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $34.2M sold.
- 0 institutional investors held CM Life Sciences, Inc. Unit (CMLFU) as of Q3 2021, down from 17 in Q2 2021.
- Funds reported $0 of CM Life Sciences, Inc. Unit stock for Q3 2021, down 100% quarter-over-quarter.
- 0 funds opened new CM Life Sciences, Inc. Unit positions in Q3 2021 and 17 closed out, a net change of -17 holders.
- The largest CM Life Sciences, Inc. Unit seller in Q3 2021 was T. Rowe Price Associates, an estimated $34.2M sold.
Based on aggregated 13F filings for Q3 2021.